FOXO4-DRI

D-retro-inverso senolytic peptideLongevity

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeLongevity / Senolytic

MechanismA D-retro-inverso peptide that disrupts the FOXO4-p53 interaction, releasing p53 to trigger apoptosis selectively in senescent cells.

EffectsIn naturally aged mice, restored fur density, improved renal function and raised activity. Cleared senescent human chondrocytes in vitro.

DosingNo human dose established.

Bottom lineAmong the highest risk-to-evidence ratios of any peptide in circulation — mouse data only, apoptotic mechanism, zero human safety work.

Not a dose · what the literature contains instead

Mouse work used 5 mg/kg intraperitoneally for three doses. No pharmacokinetic study has been published in any species.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Never tested in humans. No human pharmacokinetic or safety data at any dose. Its mechanism is deliberate induction of p53-driven apoptosis, which is not a mechanism to approach without dose-finding data.

No interaction data exists in any species.

CV 1 of 5 — Endothelial-cell senescence work exists in vitro via p53 signalling. No in vivo cardiovascular data, and none in humans.